{
  "id": "5a70dbe599e2c3af26000004",
  "type": "list",
  "question": "Which two genes are implicated in Juvenile polyposis syndrome?",
  "ideal_answer": "Juvenile polyposis syndrome (JPS) is a rare autosomal dominant disorder predisposing to gastrointestinal hamartomatous polyps and cancer with a pathogenic SMAD4 or BMPR1A germline mutation being identified in about 40-50% of patients.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25097590",
    "http://www.ncbi.nlm.nih.gov/pubmed/26122142",
    "http://www.ncbi.nlm.nih.gov/pubmed/27375208",
    "http://www.ncbi.nlm.nih.gov/pubmed/26171675",
    "http://www.ncbi.nlm.nih.gov/pubmed/17873119",
    "http://www.ncbi.nlm.nih.gov/pubmed/25389115",
    "http://www.ncbi.nlm.nih.gov/pubmed/25931195",
    "http://www.ncbi.nlm.nih.gov/pubmed/25846706",
    "http://www.ncbi.nlm.nih.gov/pubmed/28428902",
    "http://www.ncbi.nlm.nih.gov/pubmed/25129392",
    "http://www.ncbi.nlm.nih.gov/pubmed/21465659",
    "http://www.ncbi.nlm.nih.gov/pubmed/22810475",
    "http://www.ncbi.nlm.nih.gov/pubmed/26159157",
    "http://www.ncbi.nlm.nih.gov/pubmed/22171123"
  ],
  "snippets": [
    {
      "text": " JPS is most frequently caused by mutations in the SMAD4 or BMPR1A genes. Herein, we report a child with juvenile polyposis syndrome (JPS) with a novel mutation in the SMAD4 gene. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28428902",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Subsequent genetic screening revealed a novel mutation in SMAD4, exon 5 (p.Ser144Stop). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28428902",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A SMAD4 mutation indicative of juvenile polyposis syndrome in a family previously diagnosed with Menetrier's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375208",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSION: The 1244_1247delACAG mutation of SMAD4 is the cause of JPS and the likely cause of MD in a large family initially diagnosed with MD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375208",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A dominant 1244_1247delACAG mutation of SMAD4 was identified in each of the subjects with JPS as well as in each of the subjects with MD. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375208",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ince his initial diagnosis of JPS further studies have confirmed an association between JPS and mutations in BMPR1A in chromosome band 10q23.2, which is in close proximity to PTEN.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25846706",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Prevalence of thoracic aortopathy in patients with juvenile Polyposis Syndrome-Hereditary Hemorrhagic Telangiectasia due to SMAD4.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25931195",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Exome sequencing identified a germline heterozygous mutation in SMAD9 (SMAD9(V90M)). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26122142",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Causative mutations for JPS have been identified in two genes to date, SMAD4 and BMPR1A. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26159157",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Somatic alterations in juvenile polyps from BMPR1A and SMAD4 mutation carriers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26171675",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Juvenile polyposis syndrome (JPS) is a rare autosomal dominant disorder predisposing to gastrointestinal hamartomatous polyps and cancer with a pathogenic SMAD4 or BMPR1A germline mutation (1st-hit) being identified in about 40-50% of patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26171675",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The JPS is caused by mutations in SMAD4 and BMPR1A. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25097590",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Germline mutations in SMAD4 and BMPR1A disrupt the transforming growth factor \u03b2 signal transduction pathway, and are associated with juvenile polyposis syndrome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25389115",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This study evaluated the differential impact of SMAD4 and BMPR1A gene mutations on cancer risk and oncological phenotype in patients with juvenile polyposis syndrome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25389115",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Juvenile polyposis syndrome (JPS) is caused by heterozygous mutations in either SMAD4 or BMPR1A. Individuals with JPS due to mutations in SMAD4 are at greater risk to manifest signs of hereditary hemorrhagic telangiectasia (HHT).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21465659",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BMPR1A and SMAD4 germline mutations have been found in patients with juvenile polyposis syndrome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25129392",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In about 50%-60% of patients diagnosed with juvenile polyposis syndrome a germline mutation in the SMAD4 or BMPR1A gene is found.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22171123",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Juvenile polyposis syndrome (JPS) is caused by heterozygous mutations in either SMAD4 or BMPR1A.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21465659",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND In patients with juvenile polyposis syndrome (JPS) the frequency of large genomic deletions in the SMAD4 and BMPR1A genes was unknown.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17873119",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "in patients with juvenile polyposis syndrome jps the frequency of large genomic deletions in the smad4 and bmpr1a genes was unknown mutation and phenotype analysis was used in 80 unrelated patients of whom 65 met the clinical criteria for jps typical jps and 15 were suspected to have jps by direct sequencing of the two genes point mutations were identified in 30 patients 46 of typical jps using mlpa large genomic deletions were found in 14 of all patients with typical jps six deletions in smad4 and three deletions in bmpr1a mutation analysis of the pten gene in the remaining 41 mutation negative cases uncovered a point mutation in two patients 5 smad4 mutation carriers had a significantly higher frequency of gastric polyposis 73 than did patients with bmpr1a mutations 8 p 0 001 all seven cases of gastric cancer occurred in families with smad4 mutations smad4 mutation carriers with gastric polyps were significantly older at gastroscopy than those without p 0 001 in 22 of the 23 unrelated smad4 mutation carriers hereditary hemorrhagic telangiectasia hht was also diagnosed clinically the documented histologic findings encompassed a wide distribution of different polyp types comparable with that described in hereditary mixed polyposis syndromes hmps screening for large deletions raised the mutation detection rate to 60 in the 65 patients with typical jps a strong genotype phenotype correlation for gastric polyposis gastric cancer and hht was identified which should have implications for counselling and surveillance histopathological results in hamartomatous polyposis syndromes must be critically interpreted.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17873119",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "juvenile polyposis syndrome is a rare autosomal dominant syndrome characterized by multiple distinct juvenile polyps in the gastrointestinal tract and an increased risk of colorectal cancer the cumulative life time risk of colorectal cancer is 39 and the relative risk is 34 juvenile polyps have a distinctive histology characterized by an abundance of edematous lamina propria with inflammatory cells and cystically dilated glands lined by cuboidal to columnar epithelium with reactive changes clinically juvenile polyposis syndrome is defined by the presence of 5 or more juvenile polyps in the colorectum juvenile polyps throughout the gastrointestinal tract or any number of juvenile polyps and a positive family history of juvenile polyposis in about 50 60 of patients diagnosed with juvenile polyposis syndrome a germline mutation in the smad4 or bmpr1a gene is found both genes play a role in the bmp tgf beta signalling pathway it has been suggested that cancer in juvenile polyposis may develop through the so called landscaper mechanism where an abnormal stromal environment leads to neoplastic transformation of the adjacent epithelium and in the end invasive carcinoma recognition of this rare disorder is important for patients and their families with regard to treatment follow up and screening of at risk individuals each clinician confronted with the diagnosis of a juvenile polyp should therefore consider the possibility of juvenile polyposis syndrome in addition juvenile polyposis syndrome provides a unique model to study colorectal cancer pathogenesis in general and gives insight in the molecular genetic basis of cancer this review discusses clinical manifestations genetics pathogenesis and management of juvenile polyposis syndrome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22171123",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "juvenile polyposis syndrome is an autosomal dominant inherited disorder characterized by multiple juvenile polyps arising in the gastrointestinal tract and an increased risk of gastrointestinal cancers specifically colon cancer bmpr1a and smad4 germline mutations have been found in patients with juvenile polyposis syndrome we identified a bmpr1a mutation which involves a duplication of coding exon 3 c 230 452 333 441dup1995 on multiple ligation dependent probe amplification in a patient with juvenile polyposis syndrome the mutation causes a frameshift producing a truncated protein p d112nfsx2 therefore the mutation is believed to be pathogenic we also identified a duplication breakpoint in which alu sequences are located these results suggest that the duplication event resulted from recombination between alu sequences to our knowledge partial duplication in the bmpr1a gene has not been reported previously this is the first case report to document coding exon 3 duplication in the bmpr1a gene in a patient with juvenile polyposis syndrome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25129392",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "juvenile polyposis syndrome is a dominant gi polyposis syndrome defined by 5 gi juvenile polyps or 1 juvenile polyps with a family history of juvenile polyposis mutations in bmpr1a or smad4 are found in 50 of individuals hereditary hemorrhagic telangiectasia is a dominant disorder characterized by epistaxis visceral arteriovenous malformations and telangiectasias hereditary hemorrhagic telangiectasia is diagnosed when 3 criteria including clinical manifestations or a family history are present a juvenile polyposis hereditary hemorrhagic telangiectasia overlap syndrome has previously been reported in 22 of patients with juvenile polyposis due to a smad4 mutation our objective was to determine the prevalence and clinical manifestations of hereditary hemorrhagic telangiectasia by curacao criteria in our juvenile polyposis smad4 patients this was a cohort study of juvenile polyposis patients in our inherited colon cancer registries hereditary hemorrhagic telangiectasia manifestations were obtained from medical records patient contact and or prospective hereditary hemorrhagic telangiectasia screening the curacao criteria was used for diagnosis of hereditary hemorrhagic telangiectasia 3 criteria diagnostic 2 criteria suspect of prevalence and clinical manifestations of hereditary hemorrhagic telangiectasia in juvenile polyposis smad4 patients forty one juvenile polyposis families were identified genetic testing was available for individuals within 18 families smad4 mutations were found in 21 relatives in 9 families eighty one percent of smad4 patients had hereditary hemorrhagic telangiectasia and 14 were suspected of having hereditary hemorrhagic telangiectasia epistaxis and asthma are the most common symptoms in our overlap patients symptomatic and subclinical arteriovenous malformations were noted near universally there was a single tertiary referral center nearly all juvenile polyposis smad4 patients have the overlap syndrome the clinical implications and need for hereditary hemorrhagic telangiectasia screening are important factors for genetic testing in juvenile polyposis health care providers must be cognizant of the juvenile polyposis hereditary hemorrhagic telangiectasia overlap syndrome and the implications for management of these patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22810475",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.disease-ontology.org/api/metadata/DOID:0050787",
    "https://meshb.nlm.nih.gov/record/ui?ui=D005796"
  ],
  "exact_answer": "SMAD4, BMPR1A"
}